S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
LON:MXCT

MaxCyte - MXCT Share Forecast, Price & News

GBX 460
0.00 (0.00%)
(As of 01/27/2023 07:40 PM ET)
Add
Compare
Today's Range
452
▼
470
50-Day Range
410
▼
550
52-Week Range
280
▼
650
Volume
3,472 shs
Average Volume
10,010 shs
Market Capitalization
£469.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MXCT stock logo

About MaxCyte (LON:MXCT) Stock

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Stock News Headlines

January 29, 2023 | finance.yahoo.com
A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress
January 4, 2023 | marketwatch.com
MaxCyte, Catamaran Bio Sign Strategic Platform License
January 30, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 21, 2022 | finance.yahoo.com
MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
December 14, 2022 | msn.com
MaxCyte Earnings Perspective: Return On Capital Employed
December 5, 2022 | finance.yahoo.com
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
November 19, 2022 | finance.yahoo.com
Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m
November 12, 2022 | seekingalpha.com
MaxCyte, Inc. (MXCT) Q3 2022 Earnings Call Transcript
January 30, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 9, 2022 | finance.yahoo.com
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
November 9, 2022 | finance.yahoo.com
MaxCyte Reports Third Quarter 2022 Financial Results
October 18, 2022 | finance.yahoo.com
Should You Invest in MaxCyte (MXCT)?
October 12, 2022 | finance.yahoo.com
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
October 6, 2022 | finance.yahoo.com
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
September 28, 2022 | finance.yahoo.com
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
September 21, 2022 | bizjournals.com
Montgomery County biotech MaxCyte unveils new HQ to expand headcount, manufacturing
September 21, 2022 | finance.yahoo.com
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
September 13, 2022 | finance.yahoo.com
Is it a Good Time to Dispose Your MaxCyte (MXCT) Shares?
August 9, 2022 | msn.com
A Preview Of MaxCyte's Earnings
July 12, 2022 | finance.yahoo.com
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
May 13, 2022 | finance.yahoo.com
MaxCyte (LON:MXCT) pulls back 22% this week, but still delivers shareholders solid 28% CAGR over 3 years
May 9, 2022 | seekingalpha.com
MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q1 2022 Results - Earnings Call Transcript
May 9, 2022 | finanznachrichten.de
MaxCyte, Inc.: MaxCyte Reports First Quarter Financial Results
May 9, 2022 | finance.yahoo.com
MaxCyte Reports First Quarter Financial Results
April 20, 2022 | finance.yahoo.com
MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022
April 13, 2022 | marketwatch.com
MaxCyte CFO Resigns, Ron Holtz Appointed in Interim; Sees 1Q Revenue Up
April 13, 2022 | proactiveinvestors.com
MaxCyte sales surge, CFO stands down
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:MXCT
CUSIP
N/A
CIK
N/A
Web
www.maxcyte.com
Phone
+1-301-9441700
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
5.91
Current Ratio
15.05
Quick Ratio
14.38

Sales & Book Value

Annual Sales
£41.99 million
Price / Sales
11.18
Cash Flow
GBX 233.27 per share
Price / Cash Flow
1.97
Book Value
GBX 249.70 per share
Price / Book
1.84

Miscellaneous

Outstanding Shares
102,047,000
Free Float
N/A
Market Cap
£469.42 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Douglas Arthur Doerfler (Age 67)
    Founder, Pres, CEO & Exec. Director
    Comp: $1.39M
  • Mr. Ronald Evan Holtz CPA (Age 65)
    Ph.D., Chief Financial Officer
    Comp: $649.38k
  • Dr. J. Stark Thompson Ph.D. (Age 81)
    Consultant
    Comp: $84.71k
  • Dr. Cenk Sumen (Age 50)
    Chief Scientific Officer
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. Maher Masoud (Age 48)
    Exec. VP, Gen. Counsel & Sec.
  • Mr. Thomas Michael Ross (Age 62)
    Exec. VP of Global Sales
  • Dr. James Brady Ph.D.
    Sr. VP of Technical Applications & Customer Support
  • Dr. Sarah Haecker Meeks Ph.D.
    Sr. VP of Bus. Devel.
  • Mr. James Lovgren
    Sr. VP of Global Marketing

Key Competitors

View All Competitors













MXCT Stock - Frequently Asked Questions

How have MXCT shares performed in 2023?

MaxCyte's stock was trading at GBX 437.50 on January 1st, 2023. Since then, MXCT shares have increased by 5.1% and is now trading at GBX 460.
View the best growth stocks for 2023 here.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 460.

How much money does MaxCyte make?

MaxCyte (LON:MXCT) has a market capitalization of £469.42 million and generates £41.99 million in revenue each year.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The official website for the company is www.maxcyte.com. The company can be reached via phone at +1-301-9441700.

This page (LON:MXCT) was last updated on 1/30/2023 by MarketBeat.com Staff